Jun Takei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9038645/publications.pdf

Version: 2024-02-01

		2257263	2272555
14	20	3	4
papers	citations	h-index	g-index
14	14	14	26
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Modified Computed Tomography Classification for Chronic Subdural Hematoma Features Good Interrater Agreement: A Single-Center Retrospective Cohort Study. World Neurosurgery, 2021, 151, e407-e417.	0.7	10
2	Significantly high concentrations of vascular endothelial growth factor in chronic subdural hematoma with trabecular formation. Clinical Neurology and Neurosurgery, 2021, 202, 106458.	0.6	5
3	Rapid Recurrence and Anaplastic Transformation of a Pilocytic Astrocytoma in an Elderly Patient: Case Report and Review of the Literature. World Neurosurgery, 2020, 142, 441-449.	0.7	4
4	Avoidance and Improvement in Visual Field Defect After Surgery for Metastatic Brain Tumors in the Parietal and the Occipital Lobe. World Neurosurgery, 2021, 155, e847-e857.	0.7	1
5	Cerebral venous thrombosis evaluated by signal changes on susceptibility-weighted imaging: a case report. Nosotchu, 2015, 37, 167-171.	0.0	0
6	PEDT-02 DIAGNOSIS, TREATMENT AND CLINICAL OUTCOME OF ATYPICAL BRAINSTEM TUMOUR IN CHILDHOOD. Neuro-Oncology Advances, 2019, 1, ii16-ii16.	0.4	0
7	ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA. Neuro-Oncology Advances, 2019, 1, ii4-ii5.	0.4	O
8	IMT-01 THERAPEUTIC EFFECT AGAINST LOWER GRADE GLIOMA INDUCED BY DENDRITIC CELL BASED IMMUNOTHERAPY. Neuro-Oncology Advances, 2019, 1, ii17-ii17.	0.4	0
9	Four Recurrent Episodes of Spontaneous Spinal Epidural Hematoma Treated with Surgical Intervention. Spinal Surgery, 2019, 33, 184-188.	0.0	O
10	IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS. Neuro-Oncology, 2020, 22, iii362-iii362.	0.6	0
11	TAMI-19. IMMUNOHISTOLOGICAL ANALYSIS OF ANGIOGENIC FACTORS OTHER THAN VEGF IN GLIOBLASTOMAS IN RELATION TO THE USE OF BEVACIZUMAB. Neuro-Oncology, 2021, 23, vi202-vi202.	0.6	O
12	PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.4	0
13	ANGI-1 Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma. Neuro-Oncology Advances, 2021, 3, vi1-vi1.	0.4	О
14	IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma. Neuro-Oncology Advances, 2021, 3, vi12-vi12.	0.4	0